Products
Preparation registered in Ukraine
V.G. Lizogub1, E.G. Kupchinska2, A.A. Bugaytsev3
1National Medical University named after Î.Î. Bogomolets, Kyiv;
2SI «National Scientific Center «M.D. Strazhesko Institute of Cardiology, NAMS
of Ukraine», Kyiv;
3Public company «Kyiv Vitamin Factory»
Cilostazol – antiplatelet drug with great prospects
Summary
At present, antiplatelet agents have been widely used in the treatment of cardiovascular diseases. In this article, based on the data of numerous clinical studies, the effectiveness of use of the inhibitor of platelet aggregation Cilostazol is demonstrated, a medication, which by some of its features exceeds the efficiency of acetylsalicylic acid.
The uniqueness of this drug is in the fact that this is the only drug with proven effectiveness in treatment of atherosclerosis of peripheral arteries, intermittent claudication. Based on the results of a number of randomized trials and meta-analysis data, data are presented regarding its effectiveness in secondary prevention of cerebral circulation disorders - stroke and transient ischemic attacks, during endovascular interventions, incl. stenting of peripheral, brachiocephalic, coronary arteries. The safety of the use of Cilostazol has been proved by the results of a number of clinical studies.
Key words: cardiovascular diseases, antiplatelet agents, secondary prophylaxis, Cilostazol